The therapeutic system described in this report derives from basic studies of the role of APP signaling and proteolysis in plasticity, and the imbalance in this receptor proteolysis that reproducibly occurs in Alzheimer's disease. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.